secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zivo Bioscience, Inc. (ZIVO)
CIK:        0001101026
Form:       8-K
Filed at:   2022-05-20T23:59:59+00:00
Accession:  0001654954-22-007313
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zivo Bioscience updates: USDA white paper, new poultry study, licensing talks with major animal health firm
--------------------------------------------------------------------------------

- Submitted white paper to USDA for poultry coccidiosis product; expects jurisdiction confirmation within 8 weeks.
- Began 21st in vivo study with AH Pharma to optimize product forms and reduce production costs.
- Ongoing licensing discussions with a major animal health company; decision expected by end of Q2 2022.
- Previous 20 studies validated efficacy and mechanism of action for the lead product candidate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1101026/000165495422007313/0001654954-22-007313-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1101026/000165495422007313/zivo_10q.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-007313

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer